Verdad Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-39,608
Closed -$192K – 287
2026
Q2
$192K Buy
+39,608
New +$158K 0.18% 158

Other funds holding ZNTL

Verdad Advisers's ZNTL Position: Q3 2026 in Review

Verdad Advisers sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2026, closing a stake of 39,608 shares — an estimated $192K sold.

Verdad Advisers first reported a position in ZNTL in Q2 2026 and held it in 1 quarter. The position peaked at $192K in Q2 2026. 118 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

  • Verdad Advisers reported no remaining Zentalis Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Verdad Advisers sold 39,608 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $192K.
  • Verdad Advisers first reported a position in Zentalis Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Verdad Advisers's Zentalis Pharmaceuticals position peaked at $192K in Q2 2026.
  • 118 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.